CannRx Announces Commercial Model of Vapor Capture Technology (VCT), a Revolutionary Extraction Technology Designed Specifically for the Cannabis Plant

Extraction Re-Imagined; Inhalation-Re-Imagined; Cannabis-Re-Imagined

News provided by

Mar 15, 2018, 11:57 ET

NEW YORK and JERUSALEM, March 15, 2018 /PRNewswire/ -- CannRx Technology Inc., is proud to announce that its Vapor Capture Technology (VCT) is now commercial. The CannRx revolutionary extraction technology is designed specifically to make readily available the potential of the cannabis plant and get the maximum benefits in the cleanest, healthiest, and most efficient way.

Watch a video about the VCT here.

The VCT-1 is the first in a line of next-generation extraction technology, creating the closest thing to vaping or smoking, only cleaner, at lower cost, superior quality, and with precision dosing

VCT has numerous benefits including:

High yield
Improved therapeutic and bio-relevant profiles
Complete extraction in single run
Clean and efficient
Full profile of cannabinoids
Pre-Activated cannabinoids
Rapid run-time
All-in-one – combined extraction and activation of cannabinoids
Fully water-soluble extract or powder (with CannTrrap)

Downloading Cannabinoids from the "Cloud"

VCT is the only extraction system designed specifically for the cannabis plant. It provides a pre-activated, highly bio-available cannabis extract with a unique cannabinoid/terpene profile that cannot be replicated using any other extraction technology.

VCT extracts the bioactive agents in the cannabis by generating a vapor or smoke cloud plume from the whole cannabis plant. The "cloud" is processed through a unique stepwise re-solubilization process that recaptures the activated full cannabis spectrum of bioactive molecules. The extract can be formulated for inhalation (aerosol or intranasal), edibles, dermal and sublingual delivery. The resultant material can be processed into a fully water-soluble powder or liquid or into an oil.

In vivo testing of the VCT technology demonstrates rapid onset with prolonged therapeutic benefit over other extraction technologies in disease models.

Dr. William Levine, Executive Chairman of CannRX Technology states, "This patent protected, high-yield cannabis extraction process provides pre-activated, better quality extracts and concentrates than anything currently on the market. This is truly breakthrough cannabis technology and we are thrilled to be ready to market the technology internationally."

How Vapor Capture Technology works

The CannRx Cannabis Reactor works by first vaporizing or combusting selected cannabis raw material. The vaporization units utilize digitally-controlled and precise heating elements to target specific evaporation points of the cannabis plant constituents. Implementing vaporization or combustion units will result with different cannabinoids combinations suitable to address different medical conditions. Moreover, combined extraction is an option using both vaporization and combustion units that will result with differentiated fragrance and flavor of the end product. This adds the ability to control for specific cannabinoids and selective optimization of various entourage combinations. The solubilization unit captures the vapor plume, dissolves it in a liquid and then stores it in the collection unit ready for downstream processing.

VCT replicates the same cannabinoid profile that would be achieved by smoking or vaping cannabis flowers. All other extraction systems alter the cannabinoid profile and then package it for vaping or other delivery systems such as edibles or oils. The VCT final product is not dependent on additional heating steps. As such, it is more controlled, potent, and enables precision dosing for medical applications and full entourage effect for recreational use.

About CannRx Technology Inc.
CannRx Technology Inc., the company that has designed and manufactures the patent-pending VCT reactor is also developing unique scientifically based and clinically tested products for the cannabis industry.

All products will be highly differentiated and efficacious designed to address serious medical conditions treatable with cannabis. The initial product scheduled for release in 2018 are is targeting sleep disorders.

The VCT Reactor will be on full display March 19-20 at CannaTech Israel. Come visit our booth!

For further information, specifications, and cost contact us [email protected] and at www.cannrx.com

Contacts:
CannRx Technology, Inc.
Dr. William Levine, +1-646-224-6966
Executive Chairman
[email protected]

SOURCE CannRx Technology Inc